Investing.com --Evercore ISI upgraded Hyatt Hotels (NYSE:H) to "outperform" from "in-line" citing an attractive entry point following the stock’s post-earnings selloff and underperformance ...

It has been about a month since the last earnings report for Evercore (EVR). Shares have lost about 26.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Evercore ISI suggests investors buy software stocks amid market uncertainty, citing AI monetization and attractive valuations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We recently published a list of 10 Oversold Financial Stocks To Buy Right Now. In this article, we are going to take a look ...

Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to outperform from in line, citing upcoming catalysts. The investment firm said it was now including the CTX320 and CTX310 in vivo ...

Also, Evercore ISI upgrades shares to Outperform from In-Line with a $14 price target, raised from $12, believing the market underappreciates the Hawaii Supreme Court decision that lowers the ...

In a report released on February 28, Kirk Materne from Evercore ISI maintained a Buy rating on AvePoint (AVPT – Research Report), with a price target of $18.00. The company’s shares closed ...

In a report released yesterday, Michael Binetti from Evercore ISI reiterated a Buy rating on TJX Companies (TJX – Research Report), with a price target of $142.00. The company’s shares closed ...

Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to ... the company in a report on Tuesday. Baird R W lowered shares of Fortrea from a “strong ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (BRSE:1CG) from In-Line to Outperform. There are 577 funds or institutions reporting ...